OvaScience Inc (OVAS) Releases Earnings Results, Beats Expectations By $0.17 EPS

OvaScience Inc (OVAS) reported quarterly earnings results on Thursday, Aug-4-2016. The company said it had a profit of $-0.62 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.17. Analysts had a consensus of $-0.79. The company posted revenue of $.19 million in the period, compared to analysts expectations of $.21 million. The company’s revenue was up 530.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.64 EPS.

OvaScience Inc closed down -0.11 points or -2.10% at $5.13 with 1,98,803 shares getting traded on Tusday. Post opening the session at $5.24, the shares hit an intraday low of $5.04 and an intraday high of $5.31 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.

In a different news, on Jun 3, 2016, Richard Aldrich (director) purchased 425,000 shares at $7.00 per share price. According to the SEC, on Jun 3, 2016, Michelle Dipp (CEO) purchased 425,000 shares at $7.00 per share price. On May 12, 2016, Paul W.d. Chapman (COO) purchased 3,100 shares at $7.37 per share price, according to the Form-4 filing with the securities and exchange commission.

OvaScience Inc. is a global fertility company. The Company is focused on the discovery development and commercialization of new fertility treatments based on egg precursor or EggPC cells which are immature egg cells found in the protective outer layer of a woman’s own ovaries. With the Company’s AUGMENT treatment energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the In vitro fertilization (IVF) process to supplement the existing mitochondria. Its OvaPrime treatment is designed to replenish a woman’s egg reserve by transferring a patient’s EggPC cells from the protective ovarian lining back into the patient’s own ovaries where they may mature into fertilizable eggs during the IVF process. The OvaTure treatment seeks to mature a woman’s own EggPC cells into eggs outside her body. The OvaXon is a joint venture with Intrexon Corporation to create new applications to prevent inherited diseases for human and animal health.

OvaScience Inc

Leave a Reply

OvaScience Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on OvaScience Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.